OmniAb stock kpis
Want to see OABI full AI Analyst Report?
Active Partners
OmniAb reported active partners of 111 in Q3 2026, up 0.9% from Q2 2026 and up 6.7% year over year. This is the highest value since 2022.
Measures how many external companies have active collaborations or licenses with OmniAb, reflecting commercial traction and demand for its antibody discovery technology. A broad, high-quality partner base reduces revenue concentration and increases potential for milestone and royalty streams, while reliance on a few large partners raises execution and revenue risk.
Active partners climbed steadily from 69 to 110, with an acceleration since 2024 that materially broadens OmniAb’s milestone and royalty runway; management’s 110 partner count and ~98% of programs with contracted economics meaningfully increases revenue visibility and supports the raised guidance. That said, the mid‑2026 flattening (107 before a small uptick) highlights variability in onboarding cadence, and milestone-driven revenue remains lumpy and tied to partner clinical timelines — partner growth lowers single-event risk but doesn’t eliminate quarter-to-quarter volatility.
OABI Active Partners
| Period | Active Partners |
|---|---|
| Q3 2026Sep 30, 2026 | 111 |
| Q2 2026Jun 30, 2026 | 110 |
| Q1 2026Mar 31, 2026 | 107 |
| Q4 2025Dec 31, 2025 | 107 |
| Q3 2025Sep 30, 2025 | 104 |
| Q2 2025Jun 30, 2025 | 100 |
| Q1 2025Mar 31, 2025 | 95 |
| Q4 2024Dec 31, 2024 | 91 |
| Q3 2024Sep 30, 2024 | 86 |
| Q2 2024Jun 30, 2024 | 83 |
| Q1 2024Mar 31, 2024 | 80 |
| Q4 2023Dec 31, 2023 | 77 |
| Q3 2023Sep 30, 2023 | 76 |
| Q2 2023Jun 30, 2023 | 74 |
| Q1 2023Mar 31, 2023 | 70 |
| Q4 2022Dec 31, 2022 | 69 |
